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Abstract The aim of this study was to investigate the regulation
of resistin, a recently identified adipocyte-secreted peptide, in the
adipose tissue of prolactin (PRL)-transgenic (tg) mice using
ribonuclease protection assay. The level of resistin mRNA
increased 3.5-fold in the adipose tissue of untreated male PRL-
tg mice compared to controls. However, there was no difference
in resistin expression in the adipose tissue of female PRL-tg mice
compared to control mice. PRL-tg male mice have elevated
serum testosterone levels and we therefore analyzed the effects of
testosterone alone on resistin mRNA expression. Furthermore,
the effects of elevated androgen levels on PRL receptor (PRLR)
mRNA expression in the adipose tissue were investigated.
Resistin mRNA increased 2.6-fold in the adipose tissue of
control male mice with elevated serum androgen levels. In
addition, PRLR mRNA expression was increased in the adipose
tissue of male mice with elevated testosterone. These results
suggest testosterone to be a regulator of resistin and PRLR
mRNA expression in the adipose tissue of male mice. ß 2001
Federation of European Biochemical Societies. Published by
Elsevier Science B.V. All rights reserved.
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1. Introduction
A new adipocyte-secreted signaling molecule, resistin, was
recently identi¢ed [1,2]. Resistin was found to antagonize in-
sulin’s action in rodents [1]. Mice treated with recombinant
resistin became glucose intolerant and insulin resistant com-
pared to vehicle-treated mice. In addition, neutralization of
resistin, using an anti-resistin antibody, enhanced insulin-
stimulated glucose uptake by adipocytes in vitro [1]. Further-
more, circulating resistin levels increased in mice with diet-
induced and genetic forms of obesity, while resistin levels
were decreased by thiazolidinediones (TZDs) [1]. In contrast,
a di¡erent study demonstrated that resistin mRNA expression
was decreased in the epididymal adipose tissue of obese ob/ob,
db/db, tub/tub and KKAy mice and Zucker diabetic fatty rats
compared to their age-matched lean littermates [3]. Fasshauer
et al. have investigated the e¡ects of isoproterenol, dexameth-
asone and triiodothyronine on resistin mRNA expression in
3T3-L1 adipocytes in vitro and they demonstrated that iso-
proterenol inhibits resistin expression via a Gs-protein-
coupled pathway [4].
Several studies indicate that prolactin (PRL) is a diabeto-
genic hormone and hyperprolactinemia induces glucose intol-
erance, hyperinsulinaemia and insulin resistance in both hu-
man patients and rodents [5^12]. The PRL receptor (PRLR) is
a member of the cytokine receptor superfamily and it medi-
ates the e¡ects of PRL on its target tissues [13]. In a recent
study, we demonstrated PRLR expression in mouse adipo-
cytes [14]. In addition, PRLR expression increased in the adi-
pose tissue during lactation and in female and male PRL-
transgenic (tg) mice compared to controls [14].
So far, there is limited information concerning how PRL
induces insulin resistance. Because resistin has been demon-
strated to antagonize insulin’s action in rodents, in the present
study we analyzed the e¡ects of hyperprolactinemia on resistin
mRNA expression in the adipose tissue of male and female
PRL-tg mice. Furthermore, male PRL-tg mice have elevated
androgen levels [15] and the e¡ect of increased serum testos-
terone on resistin expression was therefore examined. In ad-
dition, we examined the independent and combined e¡ects of
elevated serum PRL and testosterone levels on regulation of
PRLR mRNA expression in the adipose tissue and liver of
male PRL-tg and control mice.
2. Materials and methods
2.1. Animals
Heterozygous male and female PRL-tg mice, over-expressing rat
PRL (rPRL), and non-tg littermates, control mice, were used in this
study [15,16]. All mice were kept in a controlled environment with free
access to water and pelleted food. The animal experiments were ap-
proved by the local ethics committee. At 12 weeks of age, male mice
were castrated via the abdominal route and slow release placebo or
testosterone pellets were implanted subcutaneously in the upper dorsal
part of the neck. According to group, male mice received either 7.5
mg (T7.5) or 30 mg (T30) testosterone or placebo pellets (Innovative
Research of America, Sarasota, FL, USA). 8 weeks after castration
and pellet implantation, male PRL-tg and control mice were eutha-
nized by heart puncture under general anesthesia (ketalar/rompun).
Epididymal adipose tissue, liver and serum samples were obtained
from all male mice. Parametrial adipose tissue was obtained from
all female mice. All tissues were fresh-frozen in liquid nitrogen and
stored at 370 until the time of RNA preparation.
2.2. RNA analysis
Total RNA was isolated from frozen tissues using Tri reagent ac-
cording to the manufacturer’s instructions (Sigma, St. Louis, MO,
USA). Mouse resistin, long PRLR isoform (L-PRLR) [17] and cyclo-
philin antisense RNA probes were used in a ribonuclease protection
0014-5793 / 01 / $20.00 ß 2001 Federation of European Biochemical Societies. Published by Elsevier Science B.V. All rights reserved.
PII: S 0 0 1 4 - 5 7 9 3 ( 0 1 ) 0 2 9 6 1 - 1
*Corresponding author. Fax: (46)-31-7733531..
E-mail address: hakan.billig@fysiologi.gu.se (H. Billig).
Abbreviations: PRL, prolactin; RPA, ribonuclease protection assay;
TZDs, thiazolidinediones; RT-PCR, reverse transcription-polymerase
chain reaction; tg, transgenic
FEBS 25356 19-10-01
FEBS 25356 FEBS Letters 507 (2001) 147^150
assay (RPA). A 365-bp mouse resistin cDNA fragment (nucleotides
145^509 [1]) generated by reverse transcription-polymerase chain re-
action (RT-PCR) using resistin-speci¢c primers (upstream primer: 5P-
CCAGCATGCCACTGTGT-3P, downstream primer: 5P-GTAGA-
GACCGGAGGACATCA-3P) was subcloned into the pCRII-TOPO
vector (Invitrogen, Carlsbad, CA, USA). The resistin construct was
veri¢ed by DNA sequencing and used as a template for making an
antisense RNA probe. A 288-bp mouse L-PRLR cDNA fragment
(nucleotides 1507^1794) subcloned into a pBluescript vector was
used as a template [14]. A 103-bp mouse cyclophilin probe (nucleo-
tides 38^140, Ambion, Austin, TX, USA) was used as an internal
standard to control the amount of RNA in each sample. The RPA
was performed using the RPAIII1 RPA kit (Ambion). RNA samples
were hybridized with antisense [32P]CTP-labeled cyclophilin-RNA
probe together with either antisense [32P]CTP-labeled resistin-RNA
probe or L-PRLR-RNA probe. Protected fragments were separated
on a denaturing 8-mmol/l urea/6% polyacrylamide gel (Novex, San
Diego, CA, USA). Dried gels were exposed to a phosphorimager
screen, developed in a phosphorimager (Molecular Dynamics Inc.,
Sunnyvale, CA, USA), and quantitative analysis was performed using
ImageQuant software (Molecular Dynamics Inc., Sunnyvale, CA,
USA). Resistin/cyclophilin and L-PRLR/cyclophilin ratios were calcu-
lated for the respective samples and the average ratio for the control
mice was set at 100% for resistin and L-PRLR, respectively.
2.3. Measurement of testosterone
After 8 weeks of treatment, serum testosterone levels were measured
in male mice by double antibody RIA according to the manufacturer’s
instructions (ICN Biomedicals, Costa Mesa, CA, USA) (Table 1).
Serum testosterone levels were signi¢cantly elevated in untreated
male PRL-tg mice and in male control mice implanted with a 30
mg testosterone pellet (T30) compared to control mice. Furthermore,
castrated male PRL-tg and control mice implanted with 7.5 mg tes-
tosterone pellets (T7.5) had normophysiological testosterone levels
compared to control mice. In addition, testosterone was not detected
in serum from castrated male mice implanted with placebo pellets.
2.4. Statistical analysis
Di¡erences in resistin and L-PRLR mRNA expression (comparing
resistin/cyclophilin or L-PRLR/cyclophilin ratios) and serum testos-
terone concentrations were analyzed using one-way ANOVA followed
by the Student^Newman^Keuls multiple range test.
3. Results
The e¡ects of chronically high PRL levels on resistin
mRNA expression were investigated in the adipose tissue iso-
lated from female and male PRL-tg mice and controls using
RPA (Fig. 1A,B). The level of resistin mRNA expression in-
creased 3.5-fold in the adipose tissue of untreated PRL-tg
male mice compared to control mice (Fig. 1B). However, no
signi¢cant di¡erence was detected in resistin expression in the
adipose tissue of female PRL-tg mice compared to controls
(Fig. 1A). Male PRL-tg mice, over-expressing rPRL, have
previously been reported to have elevated serum testosterone
levels compared to control mice [15]. In order to study the
e¡ects of elevated PRL levels and androgen levels independ-
ently, 12 weeks old male PRL-tg and control mice were cas-
trated and placebo or testosterone (T7.5 or T30) pellets were
implanted (Table 1). Animals were treated for 8 weeks. The
level of resistin mRNA was increased (2.6-fold) in control
male mice with elevated testosterone levels, control +T30
(Fig. 1B). In order to determine whether PRL in the absence
of testosterone or in combination with normophysiological
Fig. 1. Expression and regulation of resistin mRNA in parametrial
adipose tissue of female (10 mice per group, P = 0.090) (A) and in
epididymal adipose tissue of male (4^8 mice per group) (B) PRL-tg
(tg) and control mice receiving treatment as described in Section 2.
The resistin/cyclophilin ratio was calculated for each sample and the
values used as the relative resistin expression (the average value for
the controls was set to 100%). Results are expressed as mean þ
S.E.M. and statistical signi¢cance assessed using one-way ANOVA
followed by Student^Newman^Keuls multiple range test. *P6 0.05
vs. control.
Table 1
Serum testosterone levels in 5 month old male PRL-tg and control
mice after 8 weeks treatment
Treatment group Testosterone (nmol/l)
Control 4.27 þ 1.56
PRL-tg 23.74 þ 2.67*
Control: castrated + placebo Not detected
PRL-tg: castrated + placebo Not detected
Control: castrated +T7.5 9.33 þ 1.28
PRL-tg: castrated +T7.5 7.39 þ 1.73
Control +T30 24.12 þ 3.26*
Values are the mean þ S.E.M. (4^8 mice/group) and statistical signif-
icance assessed using one-way ANOVA followed by Student^New-
man^Keuls multiple range test. *P6 0.05 vs. control.
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testosterone levels a¡ects resistin expression, resistin mRNA
was analyzed in the adipose tissue of castrated male PRL-tg
mice implanted with either placebo or T7.5 pellets. The level
of resistin mRNA was unchanged in the adipose tissue of
castrated PRL-tgs implanted with either placebo or T7.5 pel-
lets (Fig. 1B). In addition, there was no di¡erence in resistin
mRNA expression in the adipose tissue of castrated control
male mice implanted with either placebo or T7.5 pellets.
Furthermore, to determine whether the level of L-PRLR
expression in adipose tissue is regulated by the elevated tes-
tosterone levels found in untreated PRL-tg male mice, L-
PRLR mRNA expression was analyzed in untreated PRL-tg
males and in castrated PRL-tg male mice implanted with pla-
cebo or T7.5 pellets. The level of L-PRLR was increased 3-
fold in the adipose tissue of both untreated and castrated
PRL-tg male mice compared to control mice (Fig. 2). How-
ever, the increased L-PRLR expression found in PRL-tg male
mice was not a¡ected by the di¡erent testosterone levels in
untreated or castrated males implanted with placebo or T7.5
pellets. Nevertheless, in the adipose tissue of mice with ele-
vated testosterone levels, control male mice implanted with
T30 pellets, L-PRLR mRNA expression increased 2-fold com-
pared to untreated controls (Fig. 2). Furthermore, there was
no di¡erence in L-PRLR expression in the adipose tissue of
castrated controls with placebo or T7.5 pellets.
The regulation of L-PRLR mRNA in the adipose tissue of
PRL-tg male mice was compared with its regulation in the
liver (Fig. 3). The level of L-PRLR mRNA was increased in
the liver of both untreated and castrated PRL-tg male mice
compared to untreated control mice. However, L-PRLR
mRNA increased more in castrated placebo-treated PRL-tg
males, compared to PRL-tgs with testosterone, the untreated
or the T7.5 pellet-treated males (Fig. 3). In addition, L-PRLR
mRNA expression increased in the liver of castrated placebo-
treated control male mice compared to castrated T7.5 pellet-
treated, untreated and T30 pellet-treated control mice. The
lowest hepatic L-PRLR expression was found in control
male mice with elevated serum testosterone levels implanted
with T30 pellets.
4. Discussion
PRL has been found to induce glucose intolerance and in-
sulin resistance in several species [5^12]. A new adipocyte-
secreted peptide, resistin, was recently identi¢ed [1,2]. Resistin
was proposed to represent a link between obesity and diabe-
tes. No resistin-receptor has so far been identi¢ed but resistin
was found to impair glucose tolerance and insulin action in
rodents. The present study demonstrates increased resistin
mRNA expression in the adipose tissue of untreated PRL-tg
male mice. The regulated resistin expression might be a link
between elevated serum PRL levels and altered glucose me-
tabolism. However, there was no di¡erence in resistin expres-
sion in the adipose tissue of female PRL-tg mice compared to
controls. In addition to elevated serum PRL levels, male PRL-
tg mice also have elevated testosterone levels. The reason for
this is that PRL stimulates LH-receptor expression in the
testicular Leydig cells of rodents, resulting in increased testos-
terone production [13,18]. When the level of serum testoster-
one was normalized or eliminated in PRL-tg males, resistin
mRNA expression was unchanged compared to control mice.
This observation suggests that for resistin expression to in-
crease in PRL-tg male mice, testosterone needs to be elevated.
Therefore, we investigated the e¡ects of prolonged elevated
testosterone treatment on resistin expression in control mice.
Fig. 2. Expression and regulation of L-PRLR mRNA in epididymal
adipose tissue of male PRL-tg and control mice receiving treatment
as described in Section 2. The L-PRLR/cyclophilin ratio was calcu-
lated for each sample (4^8 mice per group) and the values used as
the relative L-PRLR expression (the average value for the controls
was set to 100%). Results are expressed as mean þ S.E.M. and statis-
tical signi¢cance assessed using one-way ANOVA followed by Stu-
dent^Newman^Keuls multiple range test. *P6 0.05 vs. control.
Fig. 3. Expression and regulation of L-PRLR mRNA in the liver of
male PRL-tg and control mice receiving treatment as described in
Section 2. The L-PRLR/cyclophilin ratio was calculated for each
sample (4^8 mice per group) and the values used as the relative L-
PRLR expression (the average value for the controls was set to
100%). Results are expressed as mean þ S.E.M. and statistical signi¢-
cance assessed using one-way ANOVA followed by Student^New-
man^Keuls multiple range test. Bars with di¡erent superscripts are
signi¢cantly di¡erent from each other (P6 0.05).
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Resistin mRNA expression increased in the adipose tissue of
mice with elevated serum testosterone concentrations. How-
ever, the induction of resistin mRNA was stronger in un-
treated PRL-tg mice compared to mice where only serum
testosterone was elevated.
The regulation of the PRLR is under hormonal control and
the expression of the PRLR has for an example been shown
to vary as a function of the stage of the estrous cycle, preg-
nancy and lactation [13]. In a recent study, our group dem-
onstrated increased levels of L-PRLR mRNA in both the
adipose tissue and the liver of female and male PRL-tg mice
[14]. These ¢ndings demonstrate an important role for PRL in
regulating PRLR expression and possibly the metabolism in
the adipose tissue and the liver. However, because male PRL-
tg mice also have elevated androgen levels, we investigated the
independent and the combined e¡ects of elevated PRL levels
and androgen levels on PRLR expression in both the adipose
tissue and the liver in the present study. Male PRL-tg and
control mice were castrated and placebo or testosterone (T7.5
or T30) pellets were implanted. Earlier studies have demon-
strated that testosterone a¡ects hepatic PRLR expression. In
male rodents, castration resulted in an increased number of
liver PRL-binding sites, while testosterone administration re-
sulted in a decrease [19,20]. In this study, PRL induced L-
PRLR mRNA in both adipose tissue and the liver. However,
serum androgen levels a¡ected liver and adipose tissue PRLR
expression di¡erently. In agreement with earlier studies, ele-
vated testosterone levels decreased the PRLR mRNA expres-
sion in the liver of both PRL-tg and control mice. In contrast,
PRLR expression was increased in the adipose tissue of con-
trol mice with elevated testosterone levels implanted with a
T30 pellet. Furthermore, the PRLR expression in the adipose
tissue of both PRL-tg and control mice was una¡ected by
castration. These results demonstrate a tissue-speci¢c regula-
tion of PRLR expression in adipose tissue and the liver.
In summary, the present study demonstrates increased re-
sistin mRNA expression in the epididymal adipose tissue of
untreated PRL-tg male mice and in male mice with elevated
serum testosterone levels. In addition, male mice with elevated
testosterone levels also have increased PRLR expression in the
adipose tissue. These results suggest testosterone to be a reg-
ulator of both resistin and PRLR expression in mouse adipose
tissue. As resistin has been demonstrated to antagonize insu-
lin’s action in rodents, the hormonal regulation of resistin and
PRLR in this study could represent a link between PRL,
testosterone and altered glucose metabolism.
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